作为私募基金行业的"顶流"，百亿元级私募机构的持仓情况备受市场关注。随着A股上市公司2025年一 季报陆续披露，多家百亿元级私募机构的最新持仓动向逐渐明晰。 深圳市前海排排网基金销售有限责任公司(以下简称"私募排排网")数据显示，按2025年4月27日已披露 2025年一季报的A股上市公司前十大流通股股东名单统计，已有23家百亿元级私募机构旗下产品现身96 家公司前十大流通股股东名单，合计持股市值达349.75亿元。 高毅资产持股市值第一 此外，上海通怡投资管理有限公司、上海迎水投资管理有限公司、珠海阿巴马私募基金投资管理有限公 司等知名私募机构旗下部分产品，也在多家上市公司前十大流通股股东名单中现身。 针对百亿元级私募机构在一季度积极调整投资布局，深圳市融智私募证券投资基金管理有限公司FOF基 金经理李春瑜对《证券日报》记者表示："这主要基于两方面考量：一方面缘于对未来市场走向的前瞻 性研判；另一方面是顺应政策环境与行业景气度的动态变化，通过深度挖掘行业与板块价值，捕捉结构 性投资机遇。" 前海钜阵资本管理(深圳)有限公司首席投资官龙舫在分析百亿元级私募机构调仓的投资逻辑时对《证券 日报》记者表示："配置调 ...

新股二级交投表现平淡，但首日交投情绪或有加速赶底迹象 新股专题 2025 年 04 月 27 日 策略类●证券研究报告 投资要点 新股周观点：上周，新股首日交投情绪出现明显降温，可能新股首日交投情绪正在 加速赶底。短期，按照正常的新股周期节奏，结合上周新股二级市场继续呈现出较 为克制的资金偏好属性，新股休整周期后段的震荡拉锯预计还将持续小段时间；但 即将步入 5 月，政治局会议上周落地及业绩即将披露完毕，外部环境或推动变化逐 渐出现；保持此前观点，谨慎之余或积极关注变盘信号及局部稀缺性标的活跃可能。 （1）新股次新板块出现剧烈震荡；假设以 2024 年以来上市的新股次新板块比较 来看，上周板块平均涨幅 0.6%，实现正收益占比约 62.2%。 （2）回顾上周市场表现，一方面新股二级交投市场继续维持此前交易周颇为谨慎 克制的交投氛围，短周期内不排除震荡拉锯还将持续小段时间；另一方面，新股首 日交投情绪则有加速赶底迹象，上周新股首日交投情绪大幅降温并触及去年 924 以来偏冷区位。短期来看，我们倾向于认为，虽然当前休整周期可能尚在后段，但 多个新股周期指标或正在重新寻求共振，随着时间推移，不排除本轮休整周期底部 ...

Group 1 - The total QFII holdings in A-shares reached 3.996 billion shares with a total market value of 51.02 billion yuan as of April 27, 2025 [1] - QFII is present among the top ten shareholders of 333 companies, with approximately 200 new entries in the top ten shareholder lists of various listed companies [1] - Key sectors for QFII investments include manufacturing and TMT (Technology, Media, and Telecommunications) [1] Group 2 - The largest QFII by share count is Morgan Stanley International, holding 169 stocks, including significant positions in Huace Testing and Yanshan Technology [1] - UBS Group ranks second with holdings in 90 stocks, notably in Tianhai Defense, Wisdom Agriculture, and Fangzheng Electric [1] Group 3 - French bank BNP Paribas has the highest market value of holdings among QFIIs, with a total of 19.552 billion yuan across 7 stocks [2] - Abu Dhabi Investment Authority and Kuwait Investment Authority are actively investing in A-shares, with Abu Dhabi holding 306 million shares valued at 6.336 billion yuan [3] - Goldman Sachs International led in new stock entries, holding 53 stocks with 22 new additions in the first quarter [3] Group 4 - QFII increased holdings in 78 stocks during the first quarter, with notable increases in China Western Power and Zhuoyue Technology [7] - The top ten stocks with increased holdings include China Western Power, Yinxin Technology, and North New Materials, spanning various industries such as electrical equipment and chemicals [9][11] Group 5 - The only stock with QFII holdings exceeding 10 billion yuan is Nanjing Bank, with a stable holding of 1.865 billion shares valued at 19.264 billion yuan [3][4] - Other significant stocks in the top ten by market value include Shanghai Bank and Zijin Mining, with various fluctuations in share counts and market values [4][6]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [2]. Core Viewpoints - The report anticipates a recovery in the pharmaceutical sector in Q2 2025, with a focus on innovative drugs, AI healthcare, and consumer healthcare [2][4]. - The report highlights that nearly 50% of the disclosed pharmaceutical companies experienced a decline in revenue in Q1 2025, while 35% reported growth in both revenue and net profit [4][13]. - The report suggests that the pharmaceutical sector is expected to see performance recovery driven by policy digestion, consumer spending recovery, and the impact of health consumption trends [4][17]. Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector's weekly return was 1.16%, ranking 15th among 31 primary sub-industry indices [11]. - The medical services sub-sector had the highest weekly increase at 3.38%, while the bioproducts sub-sector saw a decline of 0.93% [11][31]. 2. Performance and Valuation - The pharmaceutical sector's current PE (TTM) is 26.25, which is below the historical average of 31.15 [21][24]. - The sector's performance over the last month showed a decline of 2.19%, with a relative performance of 1.51% compared to the CSI 300 index [18][27]. 3. Market Tracking - The report indicates that the chemical pharmaceutical sub-sector had the highest one-year increase at 12.82%, while the medical commercial sub-sector had the largest decline at 14.33% [34][35]. - The report notes that the medical services sub-sector had the highest weekly increase, while the bioproducts sub-sector had the largest weekly decline [40]. 4. Industry and Company Dynamics - The report outlines recent important policies, including the implementation plan for the digital transformation of the pharmaceutical industry from 2025 to 2030, aiming for comprehensive digital transformation by 2030 [12][49]. - The report lists several companies with significant clinical trial approvals and product registrations, indicating ongoing innovation and development within the sector [51][52].

基金分析专题报告(深度) 证券研究报告 数说公募权益及FOF基金一季报 ——科技仍为重仓方向，中小盘、港股配置强度提升 王子薇 分析师SAC执业编号：S1130524010001 王聃聃 分析师SAC执业编号：S1130521100001 张剑辉 分析师SAC执业编号：S1130519100003 2025/4/25 主动权益基金2025年一季报总结 风险提示：地缘政治风险；海外加息缓和进程不及预期；国内政策及经济复苏不及预期；基金相关信息及数据仅作为基金研究使用，不作为募集材料或者宣传材料；本文涉及所有基金历史业绩均不代表未来表现 4 1. 基金市场概况：业绩回顾 ◼ 基金市场概况：一季度A股市场整体震荡但韧性十足，日度成交额突破万亿成为常态化，AI、消费、创新药以及资源股热点轮动。各主 要宽基指数收益率均落在-2%至5%的区间，港股实现大幅反弹。各风格指数略有分化，小盘和成长风格显著占优，大盘蓝筹相对弱势。 行业指数方面，受益于开工季节性效应以及全球关税政策变动，汽车制造业和资源品表现较好，AI算力与消费电子复苏催化科技行业也 有阶段表现，消费、医药、农业、大金融板块有所分化。主动权益基金规模环比上涨1. ...

Company Overview - Innotech announced a 2024 dividend plan proposing a cash distribution of 5.6 yuan per 10 shares (including tax), totaling approximately 75.23 million yuan, which represents 30.48% of the net profit, marking the third cumulative cash distribution since the company's listing [2] - The company reported a revenue of 621 million yuan for the year, reflecting a year-on-year growth of 29.99%, and a net profit of 247 million yuan, up 41.92% year-on-year, with a basic earnings per share of 1.81 yuan and a weighted average return on equity of 12.74% [2] Dividend History - The historical dividend distribution plans since the company's listing are as follows: - 2024: 10 shares pay 5.6 yuan (total cash of 0.75 billion yuan, dividend yield of 1.52%) - 2023: 10 shares pay 4 yuan (total cash of 0.54 billion yuan, dividend yield of 1.53%) - 2022: 10 shares pay 1.66 yuan (total cash of 0.23 billion yuan, dividend yield of 0.57%) [2] Market Performance - The stock experienced a net outflow of 2.36 million yuan from major funds today, with a total net outflow of approximately 9.88 million yuan over the past five days [3] - The latest margin financing balance for the stock is 239 million yuan, which has decreased by 13.36 million yuan over the past five days, representing a decline of 5.29% [4] Industry Context - Innotech belongs to the pharmaceutical and biotechnology sector, which has seen 255 companies announce their 2024 dividend plans. The highest cash distribution was from WuXi AppTec at 7.692 billion yuan, followed by Yunnan Baiyao and Aier Eye Hospital with distributions of 2.114 billion yuan and 1.487 billion yuan, respectively [4]

以最新收盘价计算，科创板平均股价为29.59元，其中股价超100元的有39只，股价最高的是寒武纪。 证券时报·数据宝统计显示，科创板股今日上涨的有275只，下跌的有299只，以收盘价为基准测算，科 创板平均股价为29.59元，其中，收盘价超过100元的有39只，股价在50元至100元之间的有89只，股价 在30元至50元的有143只。 科创板股中，收盘价最高的是寒武纪，今日报收689.96元，下跌0.29%，其次是惠泰医疗、恒玄科技 等，最新收盘价分别为433.06元、382.45元。 科创板百元股中，今日平均下跌0.78%，具体来看，今日上涨的有18只，涨幅居前的有源杰科技、达梦 数据、茂莱光学等。下跌的有21只，跌幅居前的有思瑞浦、晶丰明源、热景生物等。 向前追溯发现，科创板百元股最新收盘价相对发行价平均溢价305.99%，溢价幅度居前的有百利天恒、 寒武纪、安集科技等，溢价幅度分别为1021.05%、971.53%、912.26%。 资金流向方面，科创板百元股今日主力资金合计净流出2.62亿元，净流入资金居前的有拓荆科技、达梦 数据、茂莱光学等，净流入资金分别为6578.21万元、4704.71万元、3 ...

医药生物行业资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002365 | 永安药业 | -4.28 | 40.91 | -13714.20 | | 002693 | 双成药业 | -9.97 | 18.88 | -13065.36 | | 600196 | 复星医药 | -0.25 | 0.82 | -8302.56 | | 003020 | 立方制药 | -10.00 | 17.63 | -8292.64 | | 603205 | 健尔康 | -7.02 | 46.99 | -7465.10 | | 002422 | 科伦药业 | -6.60 | 2.41 | -7319.24 | | 002044 | 美年健康 | -1.92 | 3.40 | -7167.05 | | 688578 | 艾力斯 | -3.48 | 1.26 | -6411.86 | | 600216 | 浙江医药 | -1.30 | 3.42 | -6123.73 | | 300401 | 花园生物 | -4 ...

4月24日祥生医疗发布2024年度分配预案，拟10派10元（含税），预计派现金额合计为1.12亿元。派现 额占净利润比例为79.62%，以该股2024年度成交均价计算，股息率为3.59%。这是公司上市以来，累计 第6次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2024.12.31 | 10派10元（含税） | 1.12 | 3.59 | | 2023.12.31 | 10派8元（含税） | 0.89 | 1.78 | | 2022.12.31 | 10派7元（含税） | 0.78 | 1.82 | | 2021.12.31 | 10转增4派5元（含税） | 0.40 | 1.03 | | 2020.12.31 | 10派8元（含税） | 0.64 | 1.14 | | 2019.12.31 | 10派10元（含税） | 0.80 | 2.08 | 证券时报·数据宝统计显示，公司今日公布了2024年报，共实现营业收入4.69亿元，同比下降3.13%，实 现净利润1.41亿元，同比下降4.0 ...

公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2024.12.31 | 10派3.83元（含税） | 2.00 | 3.63 | | 2023.12.31 | 10派3.045元（含税） | 1.59 | 2.42 | | 2022.12.31 | 10派1.260239元（含税） | 0.64 | 0.98 | | 2021.12.31 | 10转增2派1.999562元（含税） | 0.51 | 1.41 | | 2020.12.31 | 10派0.65元（含税） | 0.16 | 0.33 | | 2019.12.31 | 10派0.61元（含税） | 0.15 | 0.46 | | 2018.12.31 | 10派1.3元（含税） | 0.27 | 0.84 | | 2007.12.31 | 10转增8股 | 0.00 | 0.00 | 证券时报·数据宝统计显示，公司今日公布了2024年报，共实现营业收入333.52亿元，同比增长4.05%， 实现净利润5.26亿元，同比增长7.53%，基本 ...